FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT	OF	CHANGES	IN BEN	IEFICIAL	OWNERSH	IΙΡ
_	_				-	

OIVIB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Rovaldi Christopher</u>						2. Issuer Name and Ticker or Trading Symbol Keros Therapeutics, Inc. [KROS]								(Ch	eck all appli	or		son(s) to Issuer 10% Owner Other (specify		
	ROS THER	irst) (APEUTICS, INCIUE, SUITE 120		ING E		3. Date of Earliest Transaction (Month/Day/Year) 04/06/2022										below)	Officer (give title below) Chief Operating Officer			specify
(Street) LEXING	TON M	A (02421 (Zip)		4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	e) <mark>X</mark> Form f	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Trans. Date (Month/It				action	2A. Deemed Execution Date,			3. 4. Securi Disposed Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3,		(A) or	5. Amou Securitie Benefici Owned F	unt of es For ially (D) Following (I) (n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A (I	A) or D)	Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)		
Common Stock 04/0					5/2022		7	M		1,72	8	A	\$16	1,	,728		D			
Common Stock 04/0				04/06	5/2022				S ⁽¹⁾		1,728 D		\$65	0			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		ransaction ode (Instr.		n of Ex		6. Date Exercisable a Expiration Date (Month/Day/Year)		Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e ercisable		epiration ate	Title	OI N Of	umber					
Employee Stock Option (right to	\$16	04/06/2022			M			1,728		(2)	04	1/07/2030	Comm		1,728	\$0.00	8,002		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

Remarks:

/s/ Esther Cho, Attorney-in-Fact

04/08/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.